Literature DB >> 33453989

Structural basis for allosteric regulation of pyruvate kinase M2 by phosphorylation and acetylation.

Suparno Nandi1, Mortezaali Razzaghi1, Dhiraj Srivastava1, Mishtu Dey2.   

Abstract

Pyruvate kinase muscle isoform 2 (PKM2) is a key glycolytic enzyme and transcriptional coactivator and is critical for tumor metabolism. In cancer cells, native tetrameric PKM2 is phosphorylated or acetylated, which initiates a switch to a dimeric/monomeric form that translocates into the nucleus, causing oncogene transcription. However, it is not known how these post-translational modifications (PTMs) disrupt the oligomeric state of PKM2. We explored this question via crystallographic and biophysical analyses of PKM2 mutants containing residues that mimic phosphorylation and acetylation. We find that the PTMs elicit major structural reorganization of the fructose 1,6-bisphosphate (FBP), an allosteric activator, binding site, impacting the interaction with FBP and causing a disruption in oligomerization. To gain insight into how these modifications might cause unique outcomes in cancer cells, we examined the impact of increasing the intracellular pH (pHi) from ∼7.1 (in normal cells) to ∼7.5 (in cancer cells). Biochemical studies of WT PKM2 (wtPKM2) and the two mimetic variants demonstrated that the activity decreases as the pH is increased from 7.0 to 8.0, and wtPKM2 is optimally active and amenable to FBP-mediated allosteric regulation at pHi 7.5. However, the PTM mimetics exist as a mixture of tetramer and dimer, indicating that physiologically dimeric fraction is important and might be necessary for the modified PKM2 to translocate into the nucleus. Thus, our findings provide insight into how PTMs and pH regulate PKM2 and offer a broader understanding of its intricate allosteric regulation mechanism by phosphorylation or acetylation.
Copyright © 2020 © 2020 Nandi et al. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acetylation; allosteric regulation; cancer metabolism; crystal structure; crystal structure oligomerization; enzyme kinetics; enzyme kinetics acetylation; fluorescence binding; glycolysis; glycolysis allosteric regulation; oligomerization; phosphorylation; post-translational modification; post-translational modification (PTM); protein phosphorylation; protein structure; pyruvate kinase; pyruvate kinase muscle isoform 2

Mesh:

Substances:

Year:  2020        PMID: 33453989      PMCID: PMC7762928          DOI: 10.1074/jbc.RA120.015800

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Pyruvate kinase M2 is a phosphotyrosine-binding protein.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Ning Wu; John M Asara; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

2.  Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45.

Authors:  Tian-Biao Zhang; Ying Zhao; Zhao-Xue Tong; Yi-Fu Guan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Succinyl-5-aminoimidazole-4-carboxamide-1-ribose 5'-Phosphate (SAICAR) Activates Pyruvate Kinase Isoform M2 (PKM2) in Its Dimeric Form.

Authors:  Ming Yan; Srinivas Chakravarthy; Joshua M Tokuda; Lois Pollack; Gregory D Bowman; Young-Sam Lee
Journal:  Biochemistry       Date:  2016-08-11       Impact factor: 3.162

4.  Identification of small molecule inhibitors of pyruvate kinase M2.

Authors:  Matthew G Vander Heiden; Heather R Christofk; Eli Schuman; Alexander O Subtelny; Hadar Sharfi; Edward E Harlow; Jun Xian; Lewis C Cantley
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

5.  PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.

Authors:  Weiwei Yang; Yan Xia; David Hawke; Xinjian Li; Ji Liang; Dongming Xing; Kenneth Aldape; Tony Hunter; W K Alfred Yung; Zhimin Lu
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

6.  Acidity generated by the tumor microenvironment drives local invasion.

Authors:  Veronica Estrella; Tingan Chen; Mark Lloyd; Jonathan Wojtkowiak; Heather H Cornnell; Arig Ibrahim-Hashim; Kate Bailey; Yoganand Balagurunathan; Jennifer M Rothberg; Bonnie F Sloane; Joseph Johnson; Robert A Gatenby; Robert J Gillies
Journal:  Cancer Res       Date:  2013-01-03       Impact factor: 12.701

Review 7.  Dual roles of PKM2 in cancer metabolism.

Authors:  Songfang Wu; Huangying Le
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-12-04       Impact factor: 3.848

8.  Immunohistological demonstration of pyruvate kinase isoenzyme type L in rat with monoclonal antibodies.

Authors:  M Domingo; C Einig; E Eigenbrodt; M Reinacher
Journal:  J Histochem Cytochem       Date:  1992-05       Impact factor: 2.479

9.  Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2.

Authors:  Suparno Nandi; Mishtu Dey
Journal:  J Biol Chem       Date:  2020-03-06       Impact factor: 5.157

10.  SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions.

Authors:  Kirstie E Keller; Irene S Tan; Young-Sam Lee
Journal:  Science       Date:  2012-10-18       Impact factor: 47.728

View more
  2 in total

Review 1.  Regulation of tumor metabolism by post translational modifications on metabolic enzymes.

Authors:  Abhisha Sawant Dessai; Poonam Kalhotra; Aaron T Novickis; Subhamoy Dasgupta
Journal:  Cancer Gene Ther       Date:  2022-08-23       Impact factor: 5.854

2.  Metabolic Reprogramming in HIV-Associated Neurocognitive Disorders.

Authors:  Charles N S Allen; Sterling P Arjona; Maryline Santerre; Claudio De Lucia; Walter J Koch; Bassel E Sawaya
Journal:  Front Cell Neurosci       Date:  2022-03-28       Impact factor: 5.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.